Teva Opened a new sterile plant in Gödöllő Hungary

Teva Opened a new sterile plant in Gödöllő Hungary

​"This plant is the symbol of the harmony between the most up-to-date technology and the people, the creativity and hard work of our human capital"
The opening ceremony was held on Oct 2nd, in the presence of Viktor Orbán, Prime Minister of Hungary,  Jeremy Levin, Teva's President and CEO and Mihály Kaszás, CEO of Teva Pharmaceutical Works Hungary Ltd.

The opening of the new sterile plant means further strengthening of Teva's role in the Hungarian and international drug production. Due to the 110 million USD investment the new plant is one of the biggest and advanced manufacturing sites in the world, with annual production capacity of 160-200 million units of injection products in 6 production lines. With the 15,000 square meters production area and modular building, the new plant is not only one of the biggest sterile pharmaceutical plants but also one of the most flexible ones in the world. Thanks to the huge production potential and flexibility, the new plant can supply patients in more than 70 countries, mainly in the U.S., Europe and Far East.

In his opening speech, Jeremy Levin highlighted Teva's commitment to the highest quality drug production, and emphasized that the company has every confidence in the skill and dedication of Teva's Hungarian employees.

Mihály Kaszás said: "We are very proud of the investment, but even more proud of our employees who dreamt of this plant, who planned it, built it, equipped it, and also who will work in it. This plant is the symbol of the harmony between the most up-to-date technology and the people, the creativity and hard work of our human capital".

Teva has been operating in Hungary since 1993 and employs more than 3,500 people.
 

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.